An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.


PURPOSE This article compares the pharmacokinetics, toxicity, and clinical efficacy of high-dose intravenous, low-dose intravenous, and intermediate-dose subcutaneous recombinant interleukin-2 (rIL-2) regimens in patients with measurable metastatic renal cell carcinoma. PATIENTS AND METHODS This trial began as a two-arm randomized study comparing two… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.